Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

A Novel HIV-1 Drug Resistant Integrase Inhibitor

Posted Jul 24 2013 8:00pm

Description of Invention:
The subject invention describes a novel and highly potent inhibitor of HIV-1 integrase (IN) that has high efficacy against the major forms of Raltegravir-resistant mutant forms of IN. Thus, this IN inhibitor can be developed as a therapeutic for patients who have developed resistance to current IN inhibitors, such as Raltegravir and Elvitegravir.

Applications:
  • HIV therapeutic


Advantages:
  • High efficacy against the major forms of Raltegravir-resistant mutant forms of IN in in vitro and whole cell assays.
  • An HIV therapeutic for patients resistant to current IN inhibitors.


Development Status:
  • Early-stage
  • In vitro data available


  • Inventors:
    Xue Z Zhao (NCI)
    Terrence R Burke (NCI)
    Yves G Pommier (NCI)
    Stephen H Hughes (NCI)
    Mathieu A Metifiot (NCI)
    Stephen J Smith (NCI)
    Barry C Johnson (NCI)
    Christophe R Marchand (NCI)


    Patent Status:
    HHS, Reference No. E-093-2013/0
    US, Application No. 61/824,306 filed 16 May 2013

    Related Technology: PCT, WO2008010964 (A1), Merck

    Relevant Publication:
    1. Marchand C, et al. [ PMID 19747122 ]
    2. Liao C, et al. [ PMID 21426159 ]



    For Licensing Information Please Contact:
    Sally Hu Ph.D., M.B.A.
    NIH Office of Technology Transfer
    6011 Executive Blvd. Suite 325 Room 21,
    Rockville, MD 20852
    United States
    Email: hus@mail.nih.gov
    Phone: 301-435-5606
    Fax: 301-402-0220


    Ref No: 2594

    Updated: 07/2013

    Post a comment
    Write a comment:

    Related Searches